JELIGO 5mg tablets medication leaflet

A10BH05 linagliptin • Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Dipeptidyl peptidase 4 (DDP-4) inhibitors

Linagliptin is a medication used to treat type 2 diabetes. It belongs to the class of DPP-4 inhibitors (dipeptidyl peptidase-4) and helps lower blood sugar levels by increasing insulin secretion and reducing glucagon production.

The medication is taken orally, usually once daily, and can be used alone or in combination with other antidiabetic medications. It is important for patients to follow a balanced diet and engage in regular physical activity to maximize the benefits of treatment.

Side effects may include upper respiratory tract infections, headaches, or allergic reactions. In rare cases, pancreatitis or hypoglycemia may occur, especially when linagliptin is used with other blood sugar-lowering medications.

Patients should inform their doctor about any other medications they are taking and strictly follow the administration instructions. Pregnant or breastfeeding women should consult a specialist before using this medication.

General data about JELIGO 5mg

Substance: linagliptin

Date of last drug list: 01-02-2025

Commercial code: W70821002

Concentration: 5mg

Pharmaceutical form: tablets

Quantity: 30

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: GENEPHARM S.A. - GRECIA

Holder: EGIS PHARMACEUTICALS PLC. - UNGARIA

Number: 15753/2024/02

Shelf life: 30 months

Pharmaceutical forms available for linagliptin

Other substances similar to linagliptin

Combinations with other substances